Abstract: Provided herein are methods and compositions for the separation of an adeno-associated virus (AAV) particle from a mixture of the AAV and at least one contaminant using anion exchange chromatography. These methods and compositions allow for improved purification of complete AAV particles from contaminants such as AAV particles that lack a complete genome (e.g., empty capsids) and AAV degradation products.

Abstract: Provided are compositions that provide reduced aggregation of AAV2 particles. Also provided are methods of making and using the compositions. The compositions provided by the present disclosure generally comprise an AAV2 and a buffer with an aggregation reduction agent, such as trehalose in a high concentration (i.e., greater than 5%).

Abstract: Provided is an adenovirus-associated virus (AAV) product containing fewer non-functional capsids, such as deamidated empty AAV capsids, deamidated AAV capsids comprising a portion of the transgene, and deamidated full capsids, than AAV products currently in use. The AAV product contains a higher ratio of functional capsids to non-functional capsids (deamidated, hydrophobic capsids), compared to a control AAV product purified solely by ultracentrifugation, by anion-exchange chromatography (AEX) without a fatty acid mobile phase. Methods of making and using the AAV product are also provided, including separating functional capsids from non-functional capsids with anion-exchange chromatography (with fatty acid mobile phase), HIC, or chromatography with a mixed mode resin. Such methods also include maintaining transfected cells in a bioreactor about two days post-transfection, optionally at about 30-38° C., and subsequently separating the functional capsids from the non-functional capsids.

Abstract: Provided herein are methods and compositions for the separation of an adeno-associated virus (AAV) particle from a mixture of the AAV and at least one contaminant using anion exchange chromatography. These methods and compositions allow for improved purification of complete AAV particles from contaminants such as AAV particles that lack a complete genome (e.g., empty capsids) and AAV degradation products.

Abstract: Provided herein are methods and compositions for the separation of an adeno-associated virus (AAV) particle from a mixture of the AAV and at least one contaminant using anion exchange chromatography. These methods and compositions allow for improved purification of complete AAV particles from contaminants such as AAV particles that lack a complete genome (e.g., empty capsids) and AAV degradation products.